# A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health

> **NCT07425821** · PHASE1 · RECRUITING · sponsor: **International AIDS Vaccine Initiative** · enrollment: 112 (estimated)

## Conditions studied

- Marburg Virus Disease

## Interventions

- **BIOLOGICAL:** rVSV∆G-MARV-GP
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07425821
- **Lead sponsor:** International AIDS Vaccine Initiative
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-27
- **Primary completion:** 2027-11
- **Final completion:** 2028-07
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07425821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07425821, "A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07425821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*